These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

197 related articles for article (PubMed ID: 19785655)

  • 1. Long-term blockade of L/N-type Ca(2+) channels by cilnidipine ameliorates repolarization abnormality of the canine hypertrophied heart.
    Takahara A; Nakamura Y; Wagatsuma H; Aritomi S; Nakayama A; Satoh Y; Akie Y; Sugiyama A
    Br J Pharmacol; 2009 Nov; 158(5):1366-74. PubMed ID: 19785655
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effects of the L/N-Type Ca
    Harada E; Sugino K; Aimoto M; Takahara A
    Biol Pharm Bull; 2021 May; 44(5):707-713. PubMed ID: 33642455
    [TBL] [Abstract][Full Text] [Related]  

  • 3. L/N-type calcium channel blocker cilnidipine ameliorates proteinuria and inhibits the renal renin-angiotensin-aldosterone system in deoxycorticosterone acetate-salt hypertensive rats.
    Toba H; Yoshida M; Tojo C; Nakano A; Oshima Y; Kojima Y; Noda K; Wang J; Kobara M; Nakata T
    Hypertens Res; 2011 Apr; 34(4):521-9. PubMed ID: 21270815
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Different effects of L/N-type and L-type calcium channel blockers on the renin-angiotensin-aldosterone system in SHR/Izm.
    Konda T; Enomoto A; Aritomi S; Niinuma K; Koganei H; Ogawa T; Nitta K
    Am J Nephrol; 2009; 30(2):155-61. PubMed ID: 19325231
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cardiovascular effects of an L/N-type Ca2+ channel blocker cilnidipine assessed in the chronic atrioventricular conduction block dogs.
    Takahara A; Sugiyama A; Satoh Y; Nakamura Y; Hashimoto K
    J Pharmacol Sci; 2004 Oct; 96(2):219-23. PubMed ID: 15492462
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effects of L- and N-Type Ca Channel Blocker Cilnidipine on Changes in Heart Rate and QT Interval During Dialysis.
    Iida T; Morimoto S; Amari Y; Ando T; Ichihara A
    Kidney Blood Press Res; 2017; 42(5):933-941. PubMed ID: 29166643
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The N-type and L-type calcium channel blocker cilnidipine suppresses renal injury in Dahl rats fed a high-salt diet.
    Aritomi S; Koganei H; Wagatsuma H; Mitsui A; Ogawa T; Nitta K; Konda T
    Heart Vessels; 2010 Nov; 25(6):549-55. PubMed ID: 20922532
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparison of effects of L/N-type and L-type calcium channel blockers on post-infarct cardiac remodelling in spontaneously hypertensive rats.
    Naseratun N; Kobara M; Watanabe Y; Toba H; Nakata T
    Clin Exp Pharmacol Physiol; 2020 Sep; 47(9):1545-1553. PubMed ID: 32323339
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Additive effects of cilnidipine and angiotensin II receptor blocker in preventing the progression of diabetic nephropathy in diabetic spontaneously hypertensive rats.
    Aritomi S; Niinuma K; Ogawa T; Konda T; Nitta K
    Clin Exp Nephrol; 2013 Feb; 17(1):41-50. PubMed ID: 23011292
    [TBL] [Abstract][Full Text] [Related]  

  • 10. L/N-type calcium channel blocker cilnidipine reduces plasma aldosterone, albuminuria, and urinary liver-type fatty acid binding protein in patients with chronic kidney disease.
    Abe M; Maruyama N; Suzuki H; Inoshita A; Yoshida Y; Okada K; Soma M
    Heart Vessels; 2013 Jul; 28(4):480-9. PubMed ID: 22914905
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparison of the cardioprotective and renoprotective effects of the L/N-type calcium channel blocker, cilnidipine, in adriamycin-treated spontaneously-hypertensive rats.
    Aritomi S; Harada E; Sugino K; Nishimura M; Nakamura T; Takahara A
    Clin Exp Pharmacol Physiol; 2015 Apr; 42(4):344-52. PubMed ID: 25582553
    [TBL] [Abstract][Full Text] [Related]  

  • 12. An N-/L-type calcium channel blocker, cilnidipine, suppresses autonomic, electrical, and structural remodelling associated with atrial fibrillation.
    Tajiri K; Guichard JB; Qi X; Xiong F; Naud P; Tardif JC; Costa AD; Aonuma K; Nattel S
    Cardiovasc Res; 2019 Dec; 115(14):1975-1985. PubMed ID: 31119260
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cilnidipine, but not amlodipine, ameliorates osteoporosis in ovariectomized hypertensive rats through inhibition of the N-type calcium channel.
    Shimizu H; Nakagami H; Yasumasa N; Mariana OK; Kyutoku M; Koriyama H; Nakagami F; Shimamura M; Rakugi H; Morishita R
    Hypertens Res; 2012 Jan; 35(1):77-81. PubMed ID: 21881574
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparison of the anti-hypertensive effects of the L/N-type calcium channel antagonist cilnidipine, and the L-type calcium channel antagonist amlodipine in hypertensive patients with cerebrovascular disease.
    Takei K; Araki N; Ohkubo T; Tamura N; Yamamoto T; Furuya D; Yanagisawa CT; Shimazu K
    Intern Med; 2009; 48(16):1357-61. PubMed ID: 19687579
    [TBL] [Abstract][Full Text] [Related]  

  • 15. L/N-type calcium channel blocker suppresses reflex aldosterone production induced by antihypertensive action.
    Aritomi S; Konda T; Yoshimura M
    Heart Vessels; 2012 Jul; 27(4):419-23. PubMed ID: 21989861
    [TBL] [Abstract][Full Text] [Related]  

  • 16. L/T-type and L/N-type calcium-channel blockers attenuate cardiac sympathetic nerve activity in patients with hypertension.
    Ogura C; Ono K; Miyamoto S; Ikai A; Mitani S; Sugimoto N; Tanaka S; Fujita M
    Blood Press; 2012 Dec; 21(6):367-71. PubMed ID: 22747420
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Histological protection by cilnidipine, a dual L/N-type Ca(2+) channel blocker, against neurotoxicity induced by ischemia-reperfusion in rat retina.
    Sakamoto K; Kawakami T; Shimada M; Yamaguchi A; Kuwagata M; Saito M; Nakahara T; Ishii K
    Exp Eye Res; 2009 May; 88(5):974-82. PubMed ID: 19166832
    [TBL] [Abstract][Full Text] [Related]  

  • 18. L/N-type calcium channel blocker cilnidipine added to renin-angiotensin inhibition improves ambulatory blood pressure profile and suppresses cardiac hypertrophy in hypertension with chronic kidney disease.
    Kanaoka T; Tamura K; Wakui H; Ohsawa M; Azushima K; Uneda K; Kobayashi R; Fujikawa T; Tsurumi-Ikeya Y; Maeda A; Yanagi M; Toya Y; Umemura S
    Int J Mol Sci; 2013 Aug; 14(8):16866-81. PubMed ID: 23959116
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Involvement of N-type Ca(2+) channels in the fibrotic process of the kidney in rats.
    Mishima K; Maeshima A; Miya M; Sakurai N; Ikeuchi H; Hiromura K; Nojima Y
    Am J Physiol Renal Physiol; 2013 Mar; 304(6):F665-73. PubMed ID: 23324177
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Powerful vascular protection by combining cilnidipine with valsartan in stroke-prone, spontaneously hypertensive rats.
    Takai S; Jin D; Aritomi S; Niinuma K; Miyazaki M
    Hypertens Res; 2013 Apr; 36(4):342-8. PubMed ID: 23190689
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.